JP2024540485A - ピリダジノン化合物およびその使用 - Google Patents

ピリダジノン化合物およびその使用 Download PDF

Info

Publication number
JP2024540485A
JP2024540485A JP2024529343A JP2024529343A JP2024540485A JP 2024540485 A JP2024540485 A JP 2024540485A JP 2024529343 A JP2024529343 A JP 2024529343A JP 2024529343 A JP2024529343 A JP 2024529343A JP 2024540485 A JP2024540485 A JP 2024540485A
Authority
JP
Japan
Prior art keywords
alkyl
optionally substituted
halogen
carbocycle
membered heterocycle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024529343A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024540485A5 (enExample
Inventor
ケビン コック,
ナタリー ホウリラク,
スティーブン シュラクター,
アラン ラッセル,
Original Assignee
エッジワイズ セラピューティクス, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エッジワイズ セラピューティクス, インコーポレイテッド filed Critical エッジワイズ セラピューティクス, インコーポレイテッド
Publication of JP2024540485A publication Critical patent/JP2024540485A/ja
Publication of JP2024540485A5 publication Critical patent/JP2024540485A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2024529343A 2021-11-17 2022-11-17 ピリダジノン化合物およびその使用 Pending JP2024540485A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163280457P 2021-11-17 2021-11-17
US63/280,457 2021-11-17
PCT/US2022/050313 WO2023091606A1 (en) 2021-11-17 2022-11-17 Pyridazinone compounds and uses thereof

Publications (2)

Publication Number Publication Date
JP2024540485A true JP2024540485A (ja) 2024-10-31
JP2024540485A5 JP2024540485A5 (enExample) 2025-11-25

Family

ID=84519449

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024529343A Pending JP2024540485A (ja) 2021-11-17 2022-11-17 ピリダジノン化合物およびその使用

Country Status (4)

Country Link
US (1) US20240336609A1 (enExample)
EP (1) EP4433473A1 (enExample)
JP (1) JP2024540485A (enExample)
WO (1) WO2023091606A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102885525B1 (ko) 2018-11-06 2025-11-13 엣지와이즈 테라퓨틱스, 인크. 피리다지논 화합물 및 이의 용도
SMT202300355T1 (it) 2018-11-06 2024-01-10 Edgewise Therapeutics Inc Composti di piridazinone e loro usi
WO2020097258A1 (en) 2018-11-06 2020-05-14 Edgewise Therapeutics, Inc. Pyridazinone compounds and uses thereof
EP4473968A3 (en) 2020-05-13 2025-03-26 Edgewise Therapeutics, Inc. Pyridazinone compounds and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100477070B1 (ko) 1994-03-25 2006-04-21 이소테크니카 인코포레이티드 중수소화작용에의한의약품의효능강화법
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
DE102007025718A1 (de) * 2007-06-01 2008-12-04 Merck Patent Gmbh Pyridazinonderivate
DE102007032507A1 (de) * 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
TWI886480B (zh) * 2017-04-06 2025-06-11 美商富曼西公司 殺真菌之噁二唑
KR102885525B1 (ko) * 2018-11-06 2025-11-13 엣지와이즈 테라퓨틱스, 인크. 피리다지논 화합물 및 이의 용도
SMT202300355T1 (it) * 2018-11-06 2024-01-10 Edgewise Therapeutics Inc Composti di piridazinone e loro usi
EP4473968A3 (en) * 2020-05-13 2025-03-26 Edgewise Therapeutics, Inc. Pyridazinone compounds and uses thereof

Also Published As

Publication number Publication date
WO2023091606A1 (en) 2023-05-25
US20240336609A1 (en) 2024-10-10
EP4433473A1 (en) 2024-09-25

Similar Documents

Publication Publication Date Title
JP7429750B2 (ja) ピリダジノン化合物およびその使用
EP4149620B1 (en) Pyridazinone compounds for the treatment of neuromuscular diseases
JP7357135B2 (ja) ピリダジノン化合物およびその使用
US12240833B2 (en) Pyridazinone compounds and uses thereof
JP7758687B2 (ja) 神経筋疾患の処置のためのピリダジノン化合物
US20230321091A1 (en) Substituted pyridazinones for use in the treatment of neuromuscular diseases
WO2023091606A1 (en) Pyridazinone compounds and uses thereof
BR112015008508B1 (pt) Compostos bloqueadores de canal de sódio, composição farmacêutica compreendendo ditos compostos e uso dos mesmos para tratar uma doença relacionada ao bloqueador de canal de sódio
HK40091925A (en) Pyridazinone compounds and uses thereof
HK40057226A (en) Pyridazinone compounds and uses thereof
HK40057226B (en) Pyridazinone compounds and uses thereof
EA049463B1 (ru) Соединения пиридазинонов и их применения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251114

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251114